Biotech Archives - Page 79 of 795

5 minute read

INmune Bio Inc. Presents Data On INB03’s Role As An Immune Check Point Modulator In The Treatment Of High-Risk Breast Cancer At AACR 2024

April 8, 8:16 AM

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast CancerBoca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- INmune

INMB

3 minute read

ORIC Pharmaceuticals Presents Preclinical Data On Two Programs At The 2024 AACR Annual Meeting

By Benzinga Newsdesk

April 8, 8:15 AM

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2

ORIC

2 minute read

Auddia Announces Issuance Of Core AI Patent Titled, U.S. Patent 11,935,520 Titled ‘Identifying Shifts In Audio Content Via Machine Learning’ Supports The Core AM/fM AI Model Used Within Faidr

By Benzinga Newsdesk

April 8, 8:04 AM

U.S. Patent 11,935,520 titled ‘Identifying Shifts in Audio Content Via Machine Learning' supports the core AM/FM AI model used within faidrCompany advances its patent application for using AI prompts to interface with

AUUD

2 minute read

Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology

By Benzinga Newsdesk

April 8, 8:02 AM

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company's BioJet™ platform for oral, systemic

BIOR

3 minute read

On Friday April 5, 2024, Legend Biotech Reported CARVYKTI Becomes The First And Only BCMA-Targeted CAR-T Cell Therapy Approved By The FDA For Second-Line Treatment Of Multiple Myeloma

By Benzinga Newsdesk

April 8, 3:42 AM

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, announced

LEGN

6 minute read

Elicio Therapeutics To Present Updated Clinical T Cell And Antigen Spreading Response Data From The Ongoing AMPLIFY-201 Phase 1 Study Of ELI-002 And Preclinical Data On ELI-007 And ELI-008 At The AACR Annual Meeting

By Benzinga Newsdesk

April 5, 4:34 PM

68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells 84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cellsThe majority of ELI-002-treated patients

ELTX

2 minute read

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects Of Pro-Inflammatory Cytokine Therapeutics WTX-518 And WTX-712 At AACR 2024 Annual Meeting

By Benzinga Newsdesk

April 5, 4:32 PM

WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical modelsWTX-712, a conditionally activated IL-21 INDUKINETM

HOWL

3 minute read

Cidara Therapeutics Presents Promising New Data On Novel Drug-Fc Conjugate Candidates At The AACR Annual Meeting 2024

By Benzinga Newsdesk

April 5, 3:15 PM

- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study- CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer mouse model- Late-breaking

CDTX

2 minute read

FDA Approves Bristol-Myers/2seventy Bio’s Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer

By Vandana Singh

April 5, 1:37 PM

FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard care.

BMY

2 minute read

Pfizer’s Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study

By Vandana Singh

April 5, 1:28 PM

New England Journal of Medicine publishes Pfizer's Paxlovid trial data, revealing insights into COVID-19 treatment efficacy, hospitalization rates, and adverse events. Learn more about the study's findings and implications.

PFE